Biomedical company RougeTx raises $58 million
RougeTx raises $58 million from BioGeneration Ventures, Angelini Ventures, Kurma Partners, Aurea/EIB, Epidarex Capital, Vesalius Biocapital, ROM Utrecht Region, p53 Invest and Kerna Ventures.
The Naarden-based company RougeTx, founded in 2021, develops medicines for conditions caused by damaged blood vessels. The company originated from research at the Leiden University Medical Center. The technology focuses on restoring the stability of blood vessels. Their main candidate drug is called RTX-001. This drug is intended for patients with HHT, a hereditary blood vessel disorder. Currently, there are no approved therapies for this disease.
The new capital will be used to bring RTX-001 to clinical trials. In addition, the company aims to expand the pipeline with other vascular disease projects. Further investment is also being made in research into vascular stability. The funding also marks the public launch of the company.
